Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 401

1.

Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.

Moyer VA; U.S. Preventive Services Task Force.

Ann Intern Med. 2012 Jun 19;156(12):880-91, W312. doi: 10.7326/0003-4819-156-12-201206190-00424. Erratum in: Ann Intern Med. 2013 Jun 4;158(11):852. Ebell, Mark [added].

PMID:
22711081
2.

Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement.

US Preventive Services Task Force.

Ann Intern Med. 2009 Nov 17;151(10):716-26, W-236. doi: 10.7326/0003-4819-151-10-200911170-00008. Erratum in: Ann Intern Med. 2010 May 18;152(10):688. Ann Intern Med. 2010 Feb 2;152(3):199-200.

3.

Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force.

Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU.

Ann Intern Med. 2011 Nov 15;155(10):687-97, W214-5. doi: 10.7326/0003-4819-155-10-201111150-00376. Epub 2011 Oct 17. Review. Erratum in: Ann Intern Med. 2012 Jan 3;156(1 Pt 1):71-2.

PMID:
22006930
4.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
5.

Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement.

U.S. Preventive Services Task Force.

Ann Intern Med. 2008 Nov 4;149(9):627-37. Epub 2008 Oct 6.

PMID:
18838716
6.

Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.

Tiews S, Steinberg W, Schneider W, Hanrath C.

J Clin Virol. 2009 Nov;46 Suppl 3:S11-5. doi: 10.1016/S1386-6532(09)70295-1.

PMID:
20129068
7.

Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.

Gyllensten U, Sanner K, Gustavsson I, Lindell M, Wikström I, Wilander E.

Br J Cancer. 2011 Aug 23;105(5):694-7. doi: 10.1038/bjc.2011.277. Epub 2011 Aug 2.

8.

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Moyer VA; U.S. Preventive Services Task Force.

Ann Intern Med. 2012 Jul 17;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459.

PMID:
22801674
9.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
10.

Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force.

Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K.

Ann Intern Med. 2011 Nov 15;155(10):698-705, W216. doi: 10.7326/0003-4819-155-10-201111150-00377. Epub 2011 Oct 17. Review.

PMID:
22006929
11.

Summaries for patients. Screening for cervical cancer: recommendations from the U.S. Preventive Services Task Force.

[No authors listed]

Ann Intern Med. 2012 Jun 19;156(12):I-44. doi: 10.7326/0003-4819-156-12-201206190-00003. No abstract available.

PMID:
22711102
13.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

PMID:
12509400
14.

Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J.

N Engl J Med. 2007 Oct 18;357(16):1589-97. Erratum in: N Engl J Med. 2008 Oct 9;359(15):1637. Johansson, Bo [added].

15.

Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.

Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.

J Clin Virol. 2009 Nov;46 Suppl 3:S5-10. doi: 10.1016/S1386-6532(09)70294-X.

PMID:
20129072
16.

Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study.

Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J; Athena HPV Study Group.

Am J Obstet Gynecol. 2013 Mar;208(3):184.e1-184.e11. doi: 10.1016/j.ajog.2012.11.020. Epub 2012 Nov 19.

PMID:
23174289
17.

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.

Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J; New Technologies for Cervical Cancer Working Group.

J Natl Cancer Inst. 2006 Jun 7;98(11):765-74.

PMID:
16757701
18.

Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement.

Siu AL; U.S. Preventive Services Task Force.

Ann Intern Med. 2016 Feb 16;164(4):279-96. doi: 10.7326/M15-2886. Epub 2016 Jan 12. Erratum in: Ann Intern Med. 2016 Mar 15;164(6):448.

PMID:
26757170
19.

Screening for cervical cancer: new alternatives and research.

Lörincz AT.

Salud Publica Mex. 2003;45 Suppl 3:S376-87. Review.

PMID:
14746031
20.

Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.

Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U.

GMS Health Technol Assess. 2010 Apr 27;6:Doc05. doi: 10.3205/hta000083.

Supplemental Content

Support Center